The safety and tolerability of beta blockers in heart failure with reduced ejection fraction: is the current underutilization of this evidence-based therapy justified?

Bibliography

• Papers of special note have been highlighted as either of interest (*) or of considerable interest (**) to readers.
   Google Scholar

• Egan BM, Basile J, Chilton RJ, et al. Cardioprotection: the role of beta-blocker therapy. J Clin Hypertens. 2005;7:409–416.
   PubMedGoogle Scholar
• Nuti SV, Wang Y, Masoudi FA, et al. Improvements in the distribution of hospital performance for the care of patients with acute myocardial infarction, heart failure, and pneumonia, 2006–2011. Med Care. 2015;53(6):485–491. DOI:10.1097/MLR.0000000000000358.
   PubMed Web of Science ®Google Scholar
• Barron AJ, Zaman N, Cole GD, et al. Systematic review of genuine versus spurious side-effects of beta-blockers in heart failure using placebo control: recommendations for patient information. Int J Cardiol. 2013;168(4):3572–3579.
   PubMed Web of Science ®Google Scholar
• http://en.wikipedia.org/wiki/Beta_blocker#Adverse_effects [cited 2015 May 29].
   Google Scholar
• Vogel JH, Chidsey CA. Cardiac adrenergic activity in experimental heart failure assessed with beta receptor blockade. Am J Cardiol. 1969;24(2):198–208. DOI:10.1016/0002-9149(69)90404-4.
   PubMed Web of Science ®Google Scholar
• Stephen SA. Unwanted effects of propranolol. Am J Cardiol. 1966;18(3):463–472.
   PubMed Web of Science ®Google Scholar
• Grandjean T, Rivier JL. Cardio-circulatory effects of beta-adrenergic blockade in organic heart disease. Br Heart J. 1968;30:50–59. DOI:10.1136/hrt.30.1.50.
   PubMedGoogle Scholar
• Waagstein F, Hjalmarson A, Varnauskas E, et al. Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J. 1975;37:1022–1036. DOI:10.1136/hrt.37.10.1022.
   PubMedGoogle Scholar
• Vukovich R, Sasahara A, Sanchez-Zambrano S, et al. Beta blockade with nadolol in patients with congestive heart failure. Lancet. 1978;1(8056):162–163.
   PubMed Web of Science ®Google Scholar
• β-Blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction: II. Morbidity results. JAMA. 1983;250(20):2814–2819. DOI:10.1001/jama.1983.03340200048027.
   PubMed Web of Science ®Google Scholar
• Jafri SM, Khaja F, McFarland T, et al. Efficacy of propranolol therapy after acute myocardial infarction related to coronary arterial anatomy and left ventricular function. Am J Cardiol. 1987;60:976–980. DOI:10.1016/0002-9149(87)90336-5.
   PubMed Web of Science ®Google Scholar
• Waagstein F, Hjalmarson A, Swedeberg K, et al. Beta-blockers in dilated cardiomyopathy: they work. Eur Heart J. 1983;4(Suppl A):173–178.
   PubMed Web of Science ®Google Scholar
• CIBIS-II investigators. The cardiac insufficiency bisoprolol study II (CIBS-II): a randomized trial. Lancet. 1999;353:9–13.
   PubMed Web of Science ®Google Scholar

*Landmark study evaluating the effect of bisoprolol in heart failure with reduced ejection fraction

• MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF). Lancet. 1999;353:9–13. DOI:10.1016/S0140-6736(99)04440-2.
   PubMed Web of Science ®Google Scholar

*Landmark trial evaluating the effect of metoprolol succinate in heart failure with reduced ejection fraction

• Packer M, Fowler MB, Roecker EB, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure. N Eng J Med. 1996;334:1349–1355. DOI:10.1056/NEJM199605233342101.
   PubMed Web of Science ®Google Scholar

*Landmark trial evaluating the effect of carvedilol in heart failure with reduced ejection fraction

• Ko DT, Hebert PR, Coffey CS, et al. Adverse effects of β-blocker therapy for patients with heart failure: a quantitative overview of randomized trials. Arch Intern Med. 2004;164(13):1389–1394. DOI:10.1001/archinte.164.13.1389.
   PubMed Web of Science ®Google Scholar

**Well-designed meta-analysis describing the prevalence of adverse effects with beta blocker use

• Barron AJ, Zaman N, Cole GD, et al. Systemic review of genuine versus spurious side-effects of beta-blockers in heart failure using placebo control: recommendations for patient information. Int J Cardiol. 2013;168(4):3572–3579. DOI:10.1016/j.ijcard.2013.05.068.
   PubMed Web of Science ®Google Scholar

**Well-designed meta-analysis describing the prevalence of adverse effects with beta blocker use

• Ko DT, Hebert PR, Coffey CS, et al. Β-Blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. JAMA. 2002;288(3):351–357. DOI:10.1001/jama.288.3.351.
   PubMed Web of Science ®Google Scholar

*Well-designed meta-analysis evaluating the prevalence of CNS-related adverse effects from beta blockade

• Barsky AJ, Saintfort R, Rogers MP, et al. Nonspecific medication side effects and the nocebo phenomenon. JAMA. 2002;287(5):622–627.
   PubMed Web of Science ®Google Scholar
• Gullestad L, Wikstrand J, Deedwania P, et al. for the MERIT-HF study group. What resting heart rate should one aim for when treating patients with heart failure with a beta-blocker?: experiences from the Metoprolol Controlled Release/Extended Release Randomized Intervention Trial in chronic heart failure (MERIT-HF). J Am Coll Cardiol. 2005;45:252–259. DOI:10.1016/j.jacc.2004.10.032.
   PubMed Web of Science ®Google Scholar
• Gottlieb SS, Fisher ML, Kjekshus J, et al. on behalf of the MERIT-HF investigators. Tolerability of β-blocker initiation and titration in the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). Circulation. 2002;105:1182–1188. DOI:10.1161/hc1002.105180.
   PubMed Web of Science ®Google Scholar
• Swedberg K, Komajda M, Bohm M, et al. for the SHIFT Investigators. Ibavradine and outcomes in chronic heart failure (SHIFT): a randomized placebo-controlled study. Lancet. 2010;376(9744):875–885. DOI:10.1016/S0140-6736(10)61198-1.
   PubMed Web of Science ®Google Scholar
• Barron AJ, Zaman N, Cole GD, et al. Systemic review of genuine versus spurious side-effects of beta-blockers in heart failure using placebo control: recommendations for patient information. Int J Cardiol. 2013;168(4):3572–3579. Epub 2013 Jun 21. DOI:10.1016/j.ijcard.2013.05.068.
   PubMed Web of Science ®Google Scholar
• Paravastu SCV, Mendonca DA D, Silva A. Beta blockers for peripheral arterial disease. Cochrane Database Syst Rev. 2013;9:CD005508. DOI:10.1002/14651858.CD005508.pub3.
   Google Scholar
• Prince DS, Carliner NH. Respiratory arrest following first dose of timolol ophthalmic solution. Chest. 1983;84(5):640–641. DOI:10.1378/chest.84.5.640.
   PubMed Web of Science ®Google Scholar
• Dorow P. Effect of beta-receptor blockers on the respiratory function of patients with chronic obstructive pulmonary disease and arterial hypertension. Arzneimittelforschung. 1987;37(12):1370–1372.
   PubMed Web of Science ®Google Scholar
• Foqari R, Zoppi A, Tettamanti F, et al. Comparative effects of celiprolol, propranolol, oxprenolol, and atenolol on respiratory function in hypertensive patients with chronic obstructive lung disease. Cardiovasc Drugs Ther. 1990;4(4):1145–1149. DOI:10.1007/BF01856511.
   PubMed Web of Science ®Google Scholar
• Jabbour A, Macdonald PS, Keogh AM, et al. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial. J Am Coll Cardiol. 2010;55(17):1780–1787. DOI:10.1016/j.jacc.2010.01.024.
   PubMed Web of Science ®Google Scholar
• Salpeter S, Ormiston T, Salpeter E. Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2005;4:CD003566. DOI:10.1002/14651858.CD003566.pub2.
   Google Scholar
• Kubota Y, Asai K, Furuse E, et al. Impact of β-blocker selectivity on long-term outcomes in congestive heart failure patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2015;10:515–523. DOI:10.2147/COPD.S79942.
   PubMed Web of Science ®Google Scholar
• Du Q, Sun Y, Ding N, et al. Beta-blockers reduced the risk of mortality and exacerbation in patients with COPD: a meta-analysis of observational studies. PLoS One. 2014;9(11):e113048. DOI:10.1371/journal.pone.0113048.
   PubMed Web of Science ®Google Scholar
• Chatterjee K. The fear of beta-blocker therapy in heart failure: time to forget. Arch Intern Med. 2004;164(13):1370–1371. DOI:10.1001/archinte.164.13.1370.
   PubMed Web of Science ®Google Scholar
• Waagstein F, Bristow MR, Swedberg K, et al. for the Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Beneficial effects of metoprolol in dilated cardiomyopathy. Lancet. 1993;342:1441–1446. DOI:10.1016/0140-6736(93)92930-R.
   PubMed Web of Science ®Google Scholar
• Weisenbaugh T, Katz I, Davis J, et al. Long term (3-month) effects of a new beta-blocker (nebivolol) on cardiac performance in dilated cardiomyopathy. J Am Coll Cardiol. 1993;21:1094–1100. DOI:10.1016/0735-1097(93)90230-X.
   PubMed Web of Science ®Google Scholar
• CIBIS Investigators. A randomized trial of beta-blockade in heart failure: the Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation. 1994;90:1765–1773. DOI:10.1161/01.CIR.90.4.1765.
   PubMed Web of Science ®Google Scholar
• Krum H, Sackenr-Bernstein JD, Goldsmith RL, et al. Double-blind, placebo controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure. Circulation. 1995;92:1499–1506. DOI:10.1161/01.CIR.92.6.1499.
   PubMed Web of Science ®Google Scholar
• Bristow MR, Gilbert EM, Abraham WT, et al. MOCHA Investigators. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation. 1996;94:2807–2816. DOI:10.1161/01.CIR.94.11.2807.
   PubMed Web of Science ®Google Scholar
• Packer M, Colucci WS, Sackner-Bernstein JD, et al. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE trial prospective randomized evaluation of carvedilol on symptoms and exercise. Circulation. 1996;94(1):2793–2799. DOI:10.1161/01.CIR.94.11.2793.
   PubMed Web of Science ®Google Scholar
• Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 1996;334:1349–1355. DOI:10.1056/NEJM199605233342101.
   PubMed Web of Science ®Google Scholar
• Colucci WS, Packer M, Bristow MR, et al. for the US Carvedilol Heart Failure Study Group. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation. 1996;94(11):2800–2806.
   PubMed Web of Science ®Google Scholar
• Australia-New Zealand Heart Failure Research Collaborative Group. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet. 1997;349:375–380. DOI:10.1016/S0140-6736(97)80008-6.
   PubMed Web of Science ®Google Scholar
• The Resolved Investigators. Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy: the randomized evaluation of strategies for left ventricular dysfunction pilot study. Circulation. 2000;101:378–384. DOI:10.1161/01.CIR.101.4.378.
   PubMed Web of Science ®Google Scholar
• The Beta-Blocker Evaluation of Survival Trial Investigators. The Beta-Blocker Evaluation of Survival Trial, I: a trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med. 2001;344:1659–1667. DOI:10.1056/NEJM200105313442202.
   PubMed Web of Science ®Google Scholar
• The CAPRICORN Investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction. The CAPRICORN randomized trial. Lancet. 2001;357(9266):1385–1390. DOI:10.1016/S0140-6736(00)04560-8.
   PubMed Web of Science ®Google Scholar
• Flather MD, Shibata MC, Coats AJS, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admissions in elderly patients with heart failure (SENIORS). Eur Heart J. 2005;26:215–225. DOI:10.1093/eurheartj/ehi115.
   PubMed Web of Science ®Google Scholar